AI Article Synopsis

  • The study investigates the use of FLT-PET imaging to predict treatment responses in patients with recurrent malignant gliomas undergoing a specific chemotherapy regimen.
  • It found that about 47% of patients showed a positive metabolic response, which correlated with significantly longer survival times compared to nonresponders.
  • FLT-PET responses emerged as more reliable predictors of overall survival than traditional MRI, indicating its potential value in assessing treatment efficacy.

Article Abstract

Purpose: Evaluation of treatment effects in malignant brain tumors is challenging because of the lack of reliable response predictors of tumor response. This study examines the predictive value of positron emission tomography (PET) using [18F] fluorothymidine (FLT), an imaging biomarker of cell proliferation, in patients with recurrent malignant gliomas treated with bevacizumab in combination with irinotecan.

Patients And Methods: Patients with recurrent malignant gliomas treated with biweekly cycles of bevacizumab and irinotecan were prospectively studied with FLT-PET at baseline, after 1 to 2 weeks, and after 6 weeks from start of treatment. A more than 25% reduction in tumor FLT uptake as measured by standardized uptake value was defined as a metabolic response. FLT responses were compared with response as shown by magnetic resonance imaging (MRI) and patient survival.

Results: Twenty-one patients were included, and 19 were assessable for metabolic response evaluation with FLT-PET. There were nine responders (47%) and 10 nonresponders (53%). Metabolic responders survived three times as long as nonresponders (10.8 v 3.4 months; P = .003), and tended to have a prolonged progression-free survival (P = .061). Both early and later FLT-PET responses were more significant predictors of overall survival (1 to 2 weeks, P = .006; 6 weeks, P = .002), compared with the MRI responses (P = .060 for both 6-week and best responses).

Conclusion: FLT-PET as an imaging biomarker seems to be predictive of overall survival in bevacizumab and irinotecan treatment of recurrent gliomas. Whether FLT-PET performed as early as 1 to 2 week after starting treatment is as predictive as the study indicates at 6 weeks warrants further investigation.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.10.5825DOI Listing

Publication Analysis

Top Keywords

malignant gliomas
12
bevacizumab irinotecan
12
[18f] fluorothymidine
8
positron emission
8
emission tomography
8
imaging biomarker
8
patients recurrent
8
recurrent malignant
8
gliomas treated
8
metabolic response
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!